Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Jamie L. Reynoso, listed as CEO, Medicare Advantage, reported two Section 16 transactions. On
Clover Health Investments, Corp. (CLOV) Form 144 notice records a proposed sale of 2,012 common shares with an aggregate market value of $5,271.44 through Morgan Stanley Smith Barney LLC on
Andrew Toy, who is listed as both Chief Executive Officer and a director of Clover Health Investments, Corp. (CLOV), reported a withholding disposition of 308,950 shares of Class A common stock on 10/01/2025 at a price of $2.62 per share to cover tax obligations arising from vested restricted stock units. After this withholding, the reporting person beneficially owns 10,165,562 shares. The filing explains these shares correspond to the automatic withholding for the vesting of 6.25% of RSUs originally granted on 01/01/2023; the remaining RSUs vest quarterly in equal 6.25% installments with a final vesting on 01/01/2027, subject to continued service.
Jamie L. Reynoso, CEO, reported a sale of 4,914 shares of Class A common stock of Clover Health Investments, Corp. (CLOV) on 09/17/2025 at a weighted average price of $3.09 per share under a Rule 10b5-1 trading plan adopted March 13, 2025. After the reported sale, the filing shows beneficial ownership of 3,053,890 shares held directly. The Form 4 was signed by an attorney-in-fact and includes a footnote that the shares were sold in multiple transactions at prices ranging from $3.06 to $3.13, and that the reporting person can provide detailed per-price sale information on request.
Karen M. Soares, General Counsel & Secretary of Clover Health Investments (CLOV), reported a transaction dated 09/15/2025 in which 6,403 shares of Class A common stock were withheld to cover tax obligations upon vesting of 6.25% of the RSUs originally granted on 09/15/2022. The report shows the shares were disposed at a price of $3.14 and that the reporting person beneficially owned 1,463,084 shares following the transaction. The filing notes the remaining RSUs vest quarterly in equal installments with a final vesting date of 09/15/2026. The Form 4 is signed by an attorney-in-fact for the reporting person on 09/17/2025.
Clover Health Investments, Corp. (CLOV) notice reports a proposed sale of 4,914 common shares through Morgan Stanley Smith Barney with an aggregate market value of $15,331.68. The form lists total outstanding shares of 420,139,394 and an approximate sale date of 09/17/2025. The shares were acquired as Restricted Stock Units on 09/14/2025 from the issuer. The filing also discloses three prior 10b5-1 sales by the same person during the past three months: 19,789 shares on 07/03/2025 for $50,978.44, 2,012 on 07/07/2025 for $5,733.40, and 6,823 on 08/04/2025 for $19,717.79. The filer affirms they are not aware of undisclosed material adverse information and indicates reliance on Rule 10b5-1 procedures where applicable.
Jamie L. Reynoso, an officer (CEO, Medicare Advantage) of Clover Health Investments, filed a Form 4 reporting automatic withholding of shares to cover taxes on vested restricted stock units. On 09/14/2025, 12,567 shares of Class A common stock were withheld at $3.06 per share following vesting of RSUs granted 03/14/2022. On 09/15/2025, 8,691 shares were withheld at $3.14 per share after vesting of RSUs granted 09/16/2022. After these withholdings, the reporting person beneficially owned 3,058,804 shares. The withheld shares reflect tax settlements rather than open-market sales.
Jamie L. Reynoso, an officer (CEO, Medicare Advantage) of Clover Health Investments, Corp. (CLOV), filed an amended Form 4 reporting a correction to previously disclosed restricted stock unit (RSU) activity and a tax-withholding disposal. The amendment shows a disposition of 85,596 shares of Class A common stock on 06/30/2025 at a reported price of $2.79 per share, representing shares automatically withheld to cover tax obligations on the final one-third vesting of a performance-based RSU grant awarded on 03/16/2023. After the transaction and amendment, Reynoso directly holds 2,887,905 shares of Class A common stock. The filing clarifies the total number of earned RSUs and updates the directly held share total to reflect transactions through 06/30/2025.
Jamie L. Reynoso, identified as an officer (CEO, Medicare Advantage) of Clover Health Investments, Corp. (CLOV), reported a transaction dated 09/13/2024 involving restricted stock units (RSUs). The filing amends a prior Form 4 to reflect that 518,000 RSUs were earned under a performance-based grant awarded on 10/31/2023. One-half of those earned RSUs vested and were settled on 09/13/2024, at a reported price of $0 per share. The filing states the reporting person directly beneficially owned 2,531,545 shares of Class A common stock after the settlement, with the remaining half of the earned RSUs scheduled to vest on 10/31/2025 subject to continued employment. The amendment was filed to reflect the full number of RSUs achieved.
Jamie L. Reynoso, an officer (CEO, Medicare Advantage) of Clover Health Investments (CLOV), amended a Form 4 to clarify equity movements tied to performance-based restricted stock units (RSUs). The amendment confirms that 52,967 shares of Class A common stock were disposed of on 06/30/2024 at a price of $1.23 per share to satisfy tax withholding related to the vesting of the second tranche of performance-based RSUs. The RSUs were awarded March 16, 2023, with one-third vested September 7, 2023, one-third on June 30, 2024, and the final third scheduled for June 30, 2025. Following the transaction, the reporting person directly holds 2,401,108 Class A shares.
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
